SutroVax picks up $85 million in Series C round for pneumococcal vaccine
SutroVax, spun off from Sutro Biopharma, also announced a contract manufacturing deal with Swiss vendor Lonza.
SutroVax nets $22M Series A for conjugate vaccine work
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.